Recently new upgrades in cytogenetic, immunophenotyping and sub-atomic science have essentially pushed our cognizance of leukemia. Disastrously, standard morphologic evaluation of exceptional myeloblastic leukemia using the French-American-English portrayal relates insufficiently with a huge bit of this new information and does not envision the response to treatment. In this review, we center around employments of sub-atomic biologic strategies to the assurance of leukemia and inspect usage of this development to recognize the inconsequential waiting sickness. We by then present a revised gathering for extreme myeloblastic leukemia as shown by whether myelodysplasia-like features are accessible or lacking. Cases may then be also portrayed using French-American-English morphology and various parameters. This gathering appears to relate better with new biologic data and with medicinal response.